compounded glp 1 ending Hims & Hers stock falls 25% as FDA curtails GLP-1s New Study Finds Compounded GLP-1s

David LaMond, Medical Director, Blue Sky MD I often get asked about the secret to sustainable weight management and metabolic health

F.Hecksher-SrensenJ.CowleyM

Quantitative analysis of adipose tissue for predicting Crohns disease postoperative endoscopic recurrence and anastomotic ulcer

Are GLP-1s Safe for People with PCOS Studies that examined GLP 1 use in PCOS reported safety profiles similar to those seen in the general population

Preston, R

The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication